[{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Gets FDA Clearance of IND Application for BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\/2a Clinical Trial of AB-2004 for Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b\/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$33.4 million","upfrontCash":"Undisclosed","newsHeadline":"University of Montana Receives $33.4 million for Development and Clinical Trials of Opioid Vaccines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Opioid vaccines","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"University of Montana \/ National Institute of Health","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"GH Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GH Research Completes Phase 1 Clinical Study with GH001 in Healthy Volunteers and Updates on Further Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"GH Research","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"inhalation","sponsorNew":"GH Research \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GH Researc.."},{"orgOrder":0,"company":"DemeRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1\/2a Study as First Clinical Trial in Opioid Use Disorder in the UK","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ N.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit\/Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Positive Results on CMND-100 trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Scisparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1\/2a Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYB003","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"Receptor Life Sciences Secures $9.7 Million Financing to Advance RLS103 (Inhaled Dry Powder CBD) into Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Inhaled Dry Powder","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Partners with Clinilabs Drug Development Corporation for Phase 1\/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cybin \/ Clinilabs Drug","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Ofichem Laboratorium","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Bi.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Submits IND Application to FDA for its Phase 1\/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives Institutional Review Board Approval for its Phase 1\/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives FDA IND Clearance for its Phase 1\/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Begins Dosing with RLS103 in PIb\/IIa Study in Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug Development Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinilabs Drug Development Corporation Begins Enrollment for Phase 1\/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Clinilabs Drug Development Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$7.8 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1\/2a First-In-Human Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Inc. Announces First Participants Dosed in its Phase 1\/2a Trial of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Achieves Research and Development Milestones Ahead of Projected Timelines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Provides Update on its Intellectual Property Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma\u2019s Medication for Treating Depression in Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Closes US$3.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Polygala Tenuifolia Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces First US Site for its Phase I\/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Partners with Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide .."},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Overnight Marketed Public Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"CYB003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Ca.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Closing of Overnight Marketed Public Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Ca.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces up to US$64 Million Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Al.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Completed Type A Meeting with the FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Proniras","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"Tezampanel","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Proniras \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/.."},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.14999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Cybin \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Bl.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces $25 Million Registered Direct Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Announces Oversubscribed Private Placement of U.S. $150 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.14999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ De.."},{"orgOrder":0,"company":"Delpor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delpor's Investigational Risperidone Implant Product Provides Schizophrenia Therapy for up to One Year after a Single Administration in Phase 1b\/2a Patient Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ N.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Receives Approval to Commence its Phase I\/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai's ELE-101 Phase 1\/2a Trial Update for Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life .."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
